Risk stratification of triple-negative breast cancer with core gene signatures associated with chemoresponse and prognosis
- 24 July 2019
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 178 (1) , 185-197
Abstract
Neoadjuvant chemotherapy studies have consistently reported a strong correlation between pathologic response and long-term outcome in triple-negative breast cancer (TNBC). We aimed to define minimal gene signatures for predicting chemoresponse by a three-step approach and to further develop a risk-stratification method of TNBC.Keywords
Funding Information
- National Research Foundation of Korea (2015R1A2A2A01008264)
- National Research Foundation of Korea (2015R1A4A1041219)
This publication has 58 references indexed in Scilit:
- Differential Response to Neoadjuvant Chemotherapy Among 7 Triple-Negative Breast Cancer Molecular SubtypesClinical Cancer Research, 2013
- Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013Annals of Oncology, 2013
- Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapiesJournal of Clinical Investigation, 2011
- Immunohistochemical surrogate markers of breast cancer molecular classes predicts response to neoadjuvant chemotherapyCancer, 2010
- Response to Neoadjuvant Therapy and Long-Term Survival in Patients With Triple-Negative Breast CancerJournal of Clinical Oncology, 2008
- Triple-Negative Breast Cancer: Clinical Features and Patterns of RecurrenceClinical Cancer Research, 2007
- Descriptive analysis of estrogen receptor (ER)‐negative, progesterone receptor (PR)‐negative, and HER2‐negative invasive breast cancer, the so‐called triple‐negative phenotypeCancer, 2007
- The Triple Negative Paradox: Primary Tumor Chemosensitivity of Breast Cancer SubtypesClinical Cancer Research, 2007
- Locoregional Relapse and Distant Metastasis in Conservatively Managed Triple Negative Early-Stage Breast CancerJournal of Clinical Oncology, 2006
- Breast Cancer Molecular Subtypes Respond Differently to Preoperative ChemotherapyClinical Cancer Research, 2005